Please use this identifier to cite or link to this item:
Title: Mesenchymal stem cells attenuate acute liver injury by altering ratio between interleukin 17 producing and regulatory natural killer T cells
Authors: Milosavljevic N.
Gazdic, Marina
Simovic Markovic, Bojana
Arsenijevic A.
Nurkovic J.https
Dolicanin Z.
Djonov V.
Lukic, Miodrag
Volarevic, Vladislav
Issue Date: 2017
Abstract: © 2017 by the American Association for the Study of Liver Diseases. Mesenchymal stem cells (MSCs) are, due to immunomodulatory characteristics, considered as novel agents in the treatment of immune-mediated acute liver failure. Although it is known that MSCs can regulate activation of T lymphocytes, their capacity to modulate function of neutrophils and natural killer T (NKT) cells, major interleukin (IL) 17–producing cells in acute liver injury, is still unknown. By using 2 well-established murine models of neutrophil and NKT cell–mediated acute liver failure (induced by carbon tetrachloride and α-galactoceramide), we investigated molecular and cellular mechanisms involved in MSC-mediated modulation of IL17 signaling during acute liver injury. Single intravenous injection of MSCs attenuate acute hepatitis and hepatotoxicity of NKT cells in a paracrine, indoleamine 2,3-dioxygenase (IDO)–dependent manner. Decreased levels of inflammatory IL17 and increased levels of immunosuppressive IL10 in serum, reduced number of interleukin 17–producing natural killer T (NKT17) cells, and increased presence of forkhead box P3 + IL10–producing natural killer T regulatory cells (NKTregs) were noticed in the injured livers of MSC-treated mice. MSCs did not significantly alter the total number of IL17-producing neutrophils, CD4+, and CD8 + T lymphocytes in the injured livers. Injection of mesenchymal stem cell–conditioned medium (MSC-CM) resulted with an increased NKTreg/NKT17 ratio in the liver and attenuated hepatitis in vivo and significantly reduced hepatotoxicity of NKT cells in vitro. This phenomenon was completely abrogated in the presence of IDO inhibitor, 1-methyltryptophan. In conclusion, the capacity of MSCs to alter NKT17/NKTreg ratio and suppress hepatotoxicity of NKT cells in an IDO-dependent manner may be used as a new therapeutic approach in IL17-driven liver inflammation. Liver Transplantation 23 1040–1050 2017 AASLD.
Type: article
DOI: 10.1002/lt.24784
ISSN: 1527-6465
SCOPUS: 2-s2.0-85024488328
Appears in Collections:Faculty of Medical Sciences, Kragujevac

Page views(s)




Files in This Item:
File Description SizeFormat 
10.1002-lt.24784.pdf828.67 kBAdobe PDFThumbnail

This item is licensed under a Creative Commons License Creative Commons